THE TAPE
BBIO · Pharmaceutical Preparations · $15.1B

BridgeBio Pharma, Inc. Common Stock

$77.36▼ −1.20%
Last close
Relative strength
59RS
of 99, against every stock▲ +26 on the month
Powering up
Developing
+6.6%
six months against Pharmaceutical Preparations
52-week range
−17.2%
from the high
$62.50$93.42
Setup
On no screen
No base, flag or squeeze in place tonight. What is and is not there
No report date on the calendar.
Growth REALProof PENDING
Quarter to Sep 30, revenue +193% on a year ago
Why it is on no screen

BBIO is off the screens on one check: relative strength.

A base has formed20.0 weeks, from 62.50 to 84.94.
Long enough to count20.0 weeks against 3 needed.
Shallow enough26.4% deep against 35% allowed.
Close to its pivot-8.9% from the pivot; listed down to -20%.
Relative strengthRS 59 against 70 needed.

Measured against the base-and-breakout thresholds. The other screens use their own numbers, so a name can miss here and still be a fair-looking chart.

Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year
Support and resistance
Support below
$75.95
-1.8% · tested 3× · last 48 sessions ago
Resistance above
$78.67
+1.7% · tested 6× · last 7 sessions ago

Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.

The read

BridgeBio Pharma, Inc. Common Stock is not on any of the screens right now. Its relative strength rating is 59, and it sits in Pharmaceutical Preparations.

Against its industry
DevelopingAhead of its industry over one and three months and not behind over six, in an industry at least partly aligned.
One month against its industry
+11.6%
Three months against its industry
+7.7%
Six months against its industry
+6.6%

Read against an equal-weighted index of Pharmaceutical Preparations, which is +10.9% against the S&P 500 over six months Partly aligned.

Peers
Catalyst roadmap

Nothing dated in the next three months that we can ingest automatically.

How it moves on earnings

On average 3.3% either way across its last 8 reports.

Checking your subscription…

Close before the report day to close after it, so it holds whether the company reported before the open or after the close.

The business
Revenue
$945.5M
+192.6% year on year
Operating margin
-38.5%
Net margin
—
Free cash flow
$-369.8M
-2.5% of market cap
Price to sales
15.9×
Price to earnings
—
not meaningful on a loss

Twelve months to Sep 30, 2026, the four latest quarters in the company’s SEC filings, with the fiscal fourth quarter worked out from the annual report. Revenue growth is the latest quarter against the same quarter a year earlier.

The latest quarter, read by fixed rules · reported Oct 29
Key takeaway
Real growth, but execution and cash generation are not yet proven.
Revenue
$353.2M
+44.9% QoQ · +192.6% YoY
Gross margin
—
Net income
−$56.7M
Loss
Free cash flow
−$44.5M
Burning · 35q runway

What the numbers say

  • Good: Revenue +192.6% year over year, +44.9% on the quarter
  • Weak: Net loss $57M
  • Weak: Burning cash: operating cash flow -$44M, free cash flow -$44M, better than -$72M last quarter · 34 quarters of cash at this burn
  • Weak: Growth externally funded: capex $290K against operating cash flow -$44M
  • Weak: Net debt $1.10B · cash $1.53B
Revenue by quarter
Free cash flow
Net income
shares +2.2% in a year · net debt $1.1B

What is not obvious

  • Weak: Stock compensation $40M added back against negative operating cash flow
  • Weak: Interest $13M a quarter against an operating loss: the debt is carried by the balance sheet, not operations

The desk’s own read

Flagged as drifting up since the report

Final read
Growth: REAL · Economic proof: PENDING
Key question: Can the growth turn into durable profit and cash after its costs and financing?
The next test is operating profit: net loss $57M.

From the company’s 10-Q and 10-K filings, by Market Desk’s rules. Every line, the takeaway and the final read are fixed rules on the filed numbers; nothing reads the press release, and none of it enters a screen or a rating. Every recent reporter.

Tracked funds

Held by 3 of 46 tracked funds at the end of Q3 2026.

Last quarter: 2 bought new, 1 trimmed.

Checking your subscription…

From 13F filings, which show long stock only and arrive up to 45 days after the quarter. The broad quant funds are left out.

Flagged by the market sweep
Closed above its 20- and 50-day on heavy volumeTape · 2026-11-05
above 20d & 50d on 1.9x volume at 77.89
Mixed: stocks have outrun random stocks by 0.2% over three sessions, not consistently enough to call (1,668 cases over 60 nights). Against their own sector they have lagged by 0.7%.
GappedTape · 2026-11-05
+5.2%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
GappedTape · 2026-10-31
+6.0%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Moved 5%+ up on earningsTape · 2026-10-31
+6.0% on earnings 2026-10-29
No measurable effect: stocks behave like random ones over the next three sessions (604 cases over 42 nights).
Unusual volumeTape · 2026-10-31
3.6 sigma
After this signal, stocks have lagged random stocks by 0.1% over the next three sessions (6,474 cases over 55 nights). Against their own sector they have lagged by 0.4%.
Reported resultsFiling · 2026-10-30
2.02
No measurable effect: stocks behave like random ones over the next three sessions (2,340 cases over 54 nights).
Closed above its 20- and 50-day on heavy volumeTape · 2026-10-30
above 20d & 50d on 1.8x volume at 70.73
Mixed: stocks have outrun random stocks by 0.2% over three sessions, not consistently enough to call (1,668 cases over 60 nights). Against their own sector they have lagged by 0.7%.
Unusual volumeTape · 2026-10-30
3.0 sigma
After this signal, stocks have lagged random stocks by 0.1% over the next three sessions (6,474 cases over 55 nights). Against their own sector they have lagged by 0.4%.

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.

In the news
Insiders

No Form 4 filings read for this company in the last six months. That can mean nobody filed, or that this name has not been on a screen long enough for us to have fetched them.

What analysts expect
Strong buy5
Buy14
Hold3
Sell0
Strong sell0

These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.

Checking your subscription…

Gamma concentration

No option open interest for this company. Most listed names have no options at all, and we only read chains for names carrying a dated event, so this is a normal reading rather than a fault.

X-ray

No completed base to compare this one with yet.

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
BridgeBio Pharma, Inc. Common Stock (BBIO) — The Tape